Navigation Links
Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
Date:5/21/2013

Mississauga, Ontario (PRWEB) May 21, 2013

Inflamax scientists worked closely with internationally renowned expert scientists of the ITN to design the study, which will provide critical insight into the usefulness of two key clinical models used in the study of allergy treatments, the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC) models. Although both the models are well recognized and supported by numerous publications, to date no direct comparison between the allergic responses evoked by them has been performed.

The study involves allergen challenge by the two methods, followed by collection of nasal secretions and blood work to identify the sequence of biomarkers and inflammatory cells involved in the early and late phase of the allergic reaction. Dr. Stephen Durham from the Imperial College London developed the NAC model, and he will be the study’s coordinating investigator. The protocol is being developed by Inflamax and the team at ITN.

“We are pleased that ITN and its group of internationally renowned scientists and clinicians, after reviewing the other available EEC facilities, chose to collaborate with Inflamax on this project. This highlights the unique and very high caliber of scientific expertise and experience that we provide. Collaborations and projects like this underline our core vision and mission to develop and provide the best, scientifically validated models to our clients.” Says Dr Piyush Patel, MD, CEO of Inflamax Research. “Inflamax provides the best of client focused CRO services with scientific expertise which is unparalleled even in the top academic institutions”.

“Sponsor organizations wishing to conduct clinical trials utilizing allergen challenge models including the EEC, need to ensure that the study is properly designed. So doing this kind of basic research reinforces the confidence in data validity, and increases the likelihood that regulators around the world accept the data. The scientific staff at Inflamax have designed and conducted many mechanistic, proof of concept and pivotal studies utilizing multiple allergen challenge models, and are the experts in both scientific design and EEC trial methodology.” says Dr. Anne Marie Salapatek, President and CSO of Inflamax.

Inflamax is developing in-house capability to measure biomarkers and has the expertise to recommend specific biomarkers to assay in order to understand the underlying mechanism of action. Typical markers for consideration may include IL1, IL5, Eosinophil Cationic Protein (ECP), tryptase and Th2 cytokines, specific immunoglobulin (IgG, IgG4, IgA, IgE, and FAB), basophil activation and HLA assays.

About Inflamax

Inflamax is a full service Contract Research Organization (CRO) specializing in Proof of Concept as well as Phase I through IV studies in allergy, asthma, ocular and dermatology utilizing EEC technology. Inflamax conducts single and multi-center Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax Research’s Mobile EECTM systems which can be positioned globally, Inflamax has 2 fixed EECs at Inflamax headquarters in Toronto, Canada. Inflamax’s EECs have been validated for study of allergy to ragweed, grass, cat and dust mite, as well as dry eye syndrome (utilizing low humidity EEC conditions).

About ITN

The Immune Tolerance Network (ITN) is an international clinical research consortium sponsored by NIAID, part of the National Institutes of Health.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10742734.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
2. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
3. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. Vital Imaging Makes Greater Commitment into MRI Research
6. Phosphagenics Signs Research Agreement with the Agricultural Research Service
7. Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
8. Researchers identify signals that direct the immune system to reject a transplanted organ
9. NIH Saves Lives: Fred Hutchinson Cancer Research Center Calls On Congress To Restore Full NIH Funding
10. The Research Foundation for The State University of New York Enters Site License Agreement with 2Market Information Inc., Publisher of Technology Transfer Tactics
11. Contraceptives Market is Expected to Reach USD 23.3 Billion Globally in 2018: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... , ... FireflySci Inc. is a go-getter type of company that continues to ... two main factors. The first is the amazing customer service that the FireflySci ... all around the world. , 2016 was a tremendous sales year for FFS and ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and ... announced today that it will host a live webcast of its ... p.m. (ET). The webcast can be accessed from ... for replay through Tuesday, January 31, 2017. ... About BD BD is a ...
(Date:1/18/2017)... --  Parent Project Muscular Dystrophy (PPMD) , a nonprofit ... dystrophy (Duchenne) , today announced a $600,000 grant to ... (NJIT) and Talem Technologies (Talem) as part of the ... assist people living with Duchenne. PPMD is funding a ... computer, software, a force sensor and a motor – ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical technology ... a 510(k) to the FDA, requesting clearance of the MyoCycle Home and the ... technology. , The submission marks a major milestone for the technology startup. ...
Breaking Biology Technology:
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
(Date:12/15/2016)... Germany , December 15, 2016 ... today announced an agreement with NuData Security, an award-winning ... The partnership will enable clients to focus on good customer ... data protection regulation. ... In order to provide a one-stop fraud prevention ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
Breaking Biology News(10 mins):